• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy.

作者信息

Kaplowitz P B, Jennings S

出版信息

J Pediatr. 1987 Jan;110(1):140-3. doi: 10.1016/s0022-3476(87)80310-4.

DOI:10.1016/s0022-3476(87)80310-4
PMID:3794875
Abstract

Cyproheptadine (Cp), an antihistamine serotonin antagonist drug with appetite-stimulating activity, was given to children with growth hormone (GH) deficiency to test the hypothesis that increased weight gain would enhance the effect of GH on linear growth. Six patients with idiopathic GH deficiency received GH 0.08 U/kg three times per week plus Cp 0.25 to 0.4 mg/kg/day for 4-month periods, alternating with 4-month periods of GH plus placebo, on average for 16 months. Overall, height velocity (HV) increased from 9.1 +/- 2.4 with GH alone to 12.1 +/- 2.1 cm/yr with GH-Cp (P = 0.01) and weight velocity (WV) increased substantially from 1.3 +/- 1.3 to 7.8 +/- 3.6 kg/yr (P = 0.01). For 10 of 11 8-month treatment intervals completed, HV was greater during GH-Cp treatment than during GH alone, and there was a good correlation between HV and WV for each 4-month observation period (r = 0.64, P less than 0.002). These findings should be considered preliminary because of the small number of patients, but suggest that weight gain induced by cyproheptadine results in improved linear growth in patients given GH and that this drug may be useful in optimizing the response to GH therapy.

摘要

相似文献

1
Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy.
J Pediatr. 1987 Jan;110(1):140-3. doi: 10.1016/s0022-3476(87)80310-4.
2
Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.真性性早熟合并生长激素缺乏儿童的身高预后:促性腺激素释放激素激动剂与生长激素联合治疗的效果
J Pediatr. 1992 May;120(5):709-15. doi: 10.1016/s0022-3476(05)80232-x.
3
A novel treatment for height growth in patients with growth hormone insensitivity syndrome by cyproheptadine hydrochloride.盐酸赛庚啶治疗生长激素不敏感综合征患者身高增长的新方法。
Clin Endocrinol (Oxf). 2018 Jun;88(6):880-888. doi: 10.1111/cen.13594. Epub 2018 Apr 14.
4
Relative importance of growth hormone and sex steroids for the growth at puberty of trunk length, limb length, and muscle width in growth hormone-deficient children.生长激素缺乏儿童青春期躯干长度、肢体长度和肌肉宽度生长中生长激素和性类固醇的相对重要性。
J Pediatr. 1976 Dec;89(6):1000-8. doi: 10.1016/s0022-3476(76)80620-8.
5
Comparison of growth and somatomedin C responses following growth hormone treatment in children with small-for-date short stature, significant idiopathic short stature and hypopituitarism.小于胎龄儿矮小、显著特发性矮小和垂体功能减退患儿生长激素治疗后生长及胰岛素样生长因子C反应的比较
Acta Endocrinol (Copenh). 1984 Jun;106(2):168-74. doi: 10.1530/acta.0.1060168.
6
IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.在初始生长激素剂量逐步增加期间,胰岛素样生长因子-I(IGF-I)和胰岛素样生长因子结合蛋白-3(IGF binding protein-3)水平是生长激素缺乏儿童和小于胎龄儿出生的矮小儿童生长激素敏感性的指标。
Horm Res. 2005;64(2):68-76. doi: 10.1159/000087692. Epub 2005 Aug 19.
7
Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.接受促性腺激素释放激素类似物和生长激素治疗的身材矮小正常女孩的成年身高
J Clin Endocrinol Metab. 2000 Feb;85(2):619-22. doi: 10.1210/jcem.85.2.6387.
8
Growth and growth hormone therapy in children with achondroplasia: a two-year experience.软骨发育不全患儿的生长及生长激素治疗:两年经验
Am J Med Genet. 1997 Oct 3;72(1):71-6.
9
Basal characteristics and first year responses to human growth hormone (GH) vary according to diagnostic criteria in children with non-acquired GH deficiency (naGHD): observations from a single center over a period of five decades.非获得性生长激素缺乏(naGHD)儿童的基础特征及对人生长激素(GH)的第一年反应因诊断标准而异:来自单一中心五十年期间的观察结果
J Pediatr Endocrinol Metab. 2018 Nov 27;31(11):1257-1266. doi: 10.1515/jpem-2018-0025.
10
Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS.患有特发性生长激素缺乏症的幼儿(0至3岁)对生长激素(GH)的反应增加,但反应性较低:来自KIGS的数据分析
J Clin Endocrinol Metab. 2005 Apr;90(4):1966-71. doi: 10.1210/jc.2004-1051. Epub 2005 Jan 5.

引用本文的文献

1
Safety of Cyproheptadine, an Orexigenic Drug. Analysis of the French National Pharmacovigilance Data-Base and Systematic Review.食欲素药物赛庚啶的安全性。法国国家药物警戒数据库分析及系统评价
Front Pediatr. 2021 Sep 29;9:712413. doi: 10.3389/fped.2021.712413. eCollection 2021.
2
Effects of cyproheptadine on body weight gain in children with nonorganic failure to thrive in Taiwan: A hospital-based retrospective study.台湾地区非器质性生长发育迟缓儿童服用赛庚啶后体重增加的效果:一项基于医院的回顾性研究。
PLoS One. 2021 Oct 19;16(10):e0258731. doi: 10.1371/journal.pone.0258731. eCollection 2021.
3
Beneficial effect of cyproheptadine on body mass index in undernourished children: a randomized controlled trial.
赛庚啶对营养不良儿童体重指数的有益作用:一项随机对照试验。
Iran J Pediatr. 2014 Dec;24(6):753-8. Epub 2014 Dec 12.
4
Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children.赛庚啶治疗儿童消化不良症状的安全性和有效性。
J Pediatr. 2013 Jul;163(1):261-7. doi: 10.1016/j.jpeds.2012.12.096. Epub 2013 Feb 16.
5
The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia.盐酸赛庚啶(periactin)和醋酸甲地孕酮(megace)对患有癌症/治疗相关恶病质儿童体重的影响。
J Pediatr Hematol Oncol. 2008 Nov;30(11):791-7. doi: 10.1097/MPH.0b013e3181864a5e.
6
Preventive treatment of migraine: effect on weight.偏头痛的预防性治疗:对体重的影响。
Curr Pain Headache Rep. 2008 Jun;12(3):201-6. doi: 10.1007/s11916-008-0035-0.